TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01332500
Drug: Sumatriptan/Naproxen combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan and Naproxen Sodium
Study: NCT01332500
Drug: other oral triptans
Normalized name: TripTone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
Study: NCT03478332
Drug: Yangxinshi pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6g/tablet
Study: NCT03478332
Drug: conventional coronary heart disease medicine
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: the conventional treatment includes medicines treating coronary heart disease
Study: NCT03478332
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangxinshi simulant
Study: NCT00042289
Drug: kanamycin
Normalized name: Kanamycin
DrugBank: Kanamycin (DB01172)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: kanamycin (2nd line TB drug)
Study: NCT00042289
Drug: amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: amikacin (2nd line TB drug)
Study: NCT00042289
Drug: terizidone/cycloserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: terizidone/cycloserine (2nd line TB drug)
Study: NCT01567124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group.
Study: NCT04779060
Drug: intrathecal fentanyle
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mic fentanyle added to heavy bupivacaine for spinal anesthesia
Study: NCT02619552
Drug: Anti-TNF
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants in this arm receive an anti-TNF for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
Study: NCT02619552
Drug: Anti-TNF
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants in this arm receive an anti-TNF for the treatment of perianal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
Study: NCT02619552
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants in this arm receive steroids for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
Study: NCT02165215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo (matched to etrolizumab) SC injection Q4W.
Study: NCT03636984
Drug: recombinant TNF-α receptor: IgG Fc fusion protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg weekly
Study: NCT04480879
Drug: AZD8154 nebuliser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebuliser suspension
Study: NCT04480879
Drug: AZD8154 Placebo Monodose DPI presented in capsules
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose correspond to AZD8154 Monodose DPI formulation
Study: NCT02492269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01706146
Drug: Non-coumadin Oral Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
Study: NCT01823900
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of a combination tablet of Rosuvastatin 20mg and Olmesartan 40mg
Study: NCT01823900
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of Rosuvastatin 20mg tablet and Olmesartan 40mg tablet
Study: NCT00932100
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV dose per standard of care at the local institution
Study: NCT01059591
Drug: GSK424887
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK424887 2mg, 10mg, 50mg, 100mg capsule
Study: NCT01059591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GSK424887 2mg, 10mg,50mg, 100mg capsule
Study: NCT03995550
Drug: LEO 142397
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A compound in development by LEO Pharma A/S
Study: NCT03995550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01210456
Drug: Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days.~154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure.~In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure.
Study: NCT00821834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: tablets~Route: oral
Study: NCT02706236
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will consist of lactose, spread throughout the day with meals and snacks, taken daily PO for 4 weeks
Study: NCT03808662
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care per physician discretion
Study: NCT00158574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02202980
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT02202980
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg FDC tablet administered orally once daily
Study: NCT02503657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excipients of MN-001/tipelukast
Study: NCT01995201
Drug: DMARD
Normalized name: Disease-modifying antirheumatic drug (DMARD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-biological disease-modifying antirheumatic drugs at stable dose
Study: NCT01995201
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: stable dose
Study: NCT03697746
Drug: Dexketoprofen Trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexketoprofen trometamol 50 mg bulb
Study: NCT03697746
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ıbuprofen 400 mg vial
Study: NCT00237848
Drug: D-serine
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00951301
Drug: placebo juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 ounces of specially prepared juice not containing mangosteen taken twice daily, AM and PM, for 6 months duration of the study participation.
Study: NCT03420300
Drug: EBR/GZR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir/grazoprevir (EBR/GZR 50mg/100mg fixed dose combination \[FDC\]): 1 table per os per day for 12 weeks
Study: NCT00515203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
Study: NCT00799656
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration once daily for 28 days
Study: NCT00865904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to VX-809 capsules.
Study: NCT01706536
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-101 Placebo AM + EP-101 Placebo PM
Study: NCT01706536
Drug: EP-101 12.5 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
Study: NCT01706536
Drug: EP-101 25 mcg
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-101 25 mcg AM + EP-101 25 mcg PM
Study: NCT01706536
Drug: EP-101 50 mcg
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-101 50 mcg AM + EP-101 50 mcg PM
Study: NCT02024568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description
Study: NCT01706536
Drug: EP-101 100 mcg
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-101 100 mcg AM + EP-101 100 mcg PM
Study: NCT02126306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT03262012
Drug: BFF MDI (PT009)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
Study: NCT03262012
Drug: Symbicort® Turbohaler® Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
Study: NCT03187002
Drug: Moderate IV Sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV sedation with fentanyl and versed
Study: NCT04149964
Drug: Acetaminophen 325 mg Oral Tablet
Normalized name: ACETAMINOPHEN 325 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Acetaminophen 325 mg every 6 hours as needed for pain
Study: NCT04149964
Drug: Acetaminophen 650 mg Oral Tablet
Normalized name: acetaminophen 650 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg scheduled every 6 hours round the clock for pain
Study: NCT03423225
Drug: ADVAGRAF®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~* Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~* Duration of treatment The investigational product will be administered for 24 weeks.
Study: NCT00741663
Drug: Spironolactone and furosemide
Normalized name: furosemide / spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in arm A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day.
Study: NCT00741663
Drug: Spironolactone and furosemide
Normalized name: furosemide / spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.
Study: NCT01697696
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match QAB149
Study: NCT03066453
Drug: Tobi Inhalant Product
Normalized name: Tobi Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled tobramycin 300 mg twice per day
Study: NCT04125706
Drug: Minocycline Topical
Normalized name: minocycline topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline will be delivered locally in the periodontal pocket
Study: NCT00463606
Drug: ABT-335 and rosuvastatin calcium
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks
Study: NCT00463606
Drug: ABT-335
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks
Study: NCT00463606
Drug: rosuvastatin calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks
Study: NCT06266962
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients underwent the instillation of epinephrine into the anterior chamber at the beginning of the cataract surgery.
Study: NCT01223365
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone bitartrate extended-release tablets were administered at doses of 15, 30, 45, 60, and 90 mg orally every 12 hours. During the open-label titration period, doses were adjusted until a stable pain control was achieved. In general, the dose of hydrocodone extended release tablets could be adjusted for efficacy or tolerability, as necessary, at any time during the open-label treatment period; however, participants were required to visit the study center before increasing the dose of study drug.
Study: NCT03482440
Drug: Salsalate Oral Tablet
Normalized name: salsalate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500mg twice daily for 5 days prior to experimental testing
Study: NCT03482440
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral table twice daily for 5 days prior to experimental testing
Study: NCT00431691
Drug: 100% O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: breathing for 30 minutes, 2 breathing periods on both study days
Study: NCT00003422
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003422
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00884169
Drug: M518101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proper quantity twice a day
Study: NCT00884169
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proper quantity twice a day
Study: NCT03822078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT01110447
Drug: VSL#3
Normalized name: VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus. Dose would be 1 sachet per day (Each sachet containing 900 Billion CFU). The duration of treatment would be for 24 weeks
Study: NCT00322257
Drug: inhaled human insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target dose titration scheme, inhalation.
Study: NCT03758001
Drug: IBI101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg; 15 mg/kg iv infusion day 1 of every 21 days
Study: NCT03758001
Drug: IBI101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg iv infusion day 1 of every 21 days
Study: NCT01466335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablet
Study: NCT02857270
Drug: LY3214996
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00884988
Drug: Lymphomyosot
Normalized name: Lymphomyosot Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 drops X3/day, until discharge
Study: NCT00884988
Drug: Placebo remedy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 drops X3/day, until discharge
Study: NCT02541526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar capsule containing placebo will be started on day six of treatment for a period of 3 days followed by two capsules of placebo daily for a period of four months
Study: NCT04526210
Drug: ALXN1840
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1840 will be administered orally as a single dose as 4 x 15 mg enteric-coated tablets with 240 milliliters of water (fasting), for a total dose of 60 mg.
Study: NCT02370745
Drug: GIP
Normalized name: GIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be co infused with GLP-1 and intravenous amino acids
Study: NCT00555971
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to Placebo prior to aspirin desensitization
Study: NCT00458848
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00458848
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04629404
Drug: LY03003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
Study: NCT04629404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
Study: NCT01179880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for each step
Study: NCT01703832
Drug: Neurexan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
Study: NCT03561142
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29. After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of: Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv
Study: NCT00893256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: once daily
Study: NCT03365037
Drug: Electret electrostatic physiotherapyFilm
Normalized name: ELECARE JR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with acute soft tissue injury treated with electret electrostatic physiotherapyFilm
Study: NCT04352361
Drug: TVB-2640
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVB-2640 tablets (25mg/50mg/75mg) one tablet at a time, once per day.
Study: NCT04352361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, matching number of placebo Tablets with active arm.
Study: NCT02364713
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04227483
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone for 4 months
Study: NCT04550260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab matching placebo for intravenous infusion
Study: NCT02679001
Drug: TNF inhibitor/TCZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current SPC/local labeling will be observed.
Study: NCT04550260
Drug: cisplatin + fluorouracil
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin + fluorouracil, as per Standard of Care
Study: NCT04550260
Drug: cisplatin + capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cisplatin + capecitabine, as per Standard of Care
Study: NCT02800252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage full-mouth periodontal ultrasonic debridement plus placebo intervention
Study: NCT01709760
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 15-25 mg/week
Study: NCT01709760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, sc twice weekly
Study: NCT02800252
Drug: 3g omega-3 plus 100mg aspirin daily for 60 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
Study: NCT00647881
Drug: Paxil CR™ Tablets 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg, single dose fed
Study: NCT02800252
Drug: omega-3 plus aspirin before periodontal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days before periodontal therapy
Study: NCT00150007
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04408755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules